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Gö6976. mRNA was quantified from microdissected intra-
pulmonary arteries. We found that broad-spectrum PKC in-
hibition reduced pulmonary vascular responsiveness to ET-1 
and acute hypoxia and, by trend, to U46619. Analogously, 
selective inhibition of conventional PKC isozymes or PKCα 
deficiency reduced ET-1-evoked pulmonary vasoconstric-
tion. The pulmonary vasopressor response to serotonin was 
unaffected by either broad PKC inhibition or PKCα deficien-
cy. Surprisingly, PKCα –/– mice showed pulmonary vascular 
hyperresponsiveness to U46619 and increased TXA2 recep-
tor (TP receptor) expression in the intrapulmonary arteries. 
To conclude, PKCα regulates ET-1-induced pulmonary va-
soconstriction. However, PKCα deficiency leads to pulmo-
nary vascular hyperresponsiveness to TXA2, possibly via in-
creased pulmonary arterial TP receptor expression. 
 © 2016 S. Karger AG, Basel 
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 Abstract 
 Pulmonary vascular hyperresponsiveness is a main charac-
teristic of pulmonary arterial hypertension (PAH). In PAH pa-
tients, elevated levels of the vasoconstrictors thromboxane 
A2 (TXA2), endothelin (ET)-1 and serotonin further contrib-
ute to pulmonary hypertension. Protein kinase C (PKC) iso-
zyme alpha (PKCα) is a known modulator of smooth muscle 
cell contraction. However, the effects of PKCα deficiency on 
pulmonary vasoconstriction have not yet been investigated. 
Thus, the role of PKCα in pulmonary vascular responsiveness 
to the TXA2 analog U46619, ET-1, serotonin and acute hyp-
oxia was investigated in isolated lungs of PKCα –/– mice and 
corresponding wild-type mice, with or without prior admin-
istration of the PKC inhibitor bisindolylmaleimide I or 
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 Pulmonary arterial hypertension (PAH) is a fatal con-
dition. Increased pulmonary vasoconstriction and pro-
gressive remodeling of the pulmonary arteries lead to el-
evated pulmonary arterial resistance and ultimately to 
right heart failure. Endothelial dysfunction, characterized 
by an imbalance between vasoconstrictive and vasodila-
tive mediators, is an important feature of PAH pathobiol-
ogy  [1] . In PAH patients, increased levels of thromboxane 
A2 (TXA2)  [2] , endothelin (ET)-1  [3] and serotonin  [4] 
as well as decreased levels of nitric oxide  [5] and prosta-
cyclin  [2] have been observed. Moreover, the pulmonary 
vasopressor response to constrictive agents is enhanced 
in PAH patients  [6] , reflecting a hypercontractile state of 
pulmonary vascular smooth muscle cells. This hyperre-
sponsiveness is believed to potentiate pulmonary vaso-
constriction induced by the imbalance of the vasoactive 
agents.
 In patients with systemic sclerosis-associated PAH, 
functional autoantibodies against the ET receptor A and/
or the angiotensin II receptor type 1 may contribute to 
increased pulmonary vasoconstriction  [7] . Pulmonary 
vascular hyperresponsiveness is also a key feature of com-
monly used experimental models of PAH including the 
monocrotaline  [8] , the T-helper (Th)2 inflammation  [9, 
10] and the hypoxia model  [11] , and it has been reported 
for clinically relevant vasoconstrictors like TXA2, ET-1, 
serotonin and alveolar hypoxia  [8, 9] . Mechanistically, 
pulmonary vascular hyperresponsiveness has been pro-
posed to be partially dependent on protein kinase C 
(PKC) signaling  [9] .
 PKC is a family of serine/threonine kinases, which are 
classified into conventional (c)PKC, novel (n)PKC and 
atypical (a)PKC isozymes  [12, 13] . Both conventional (α, 
β I , β II and γ) and novel PKC isozymes (δ, ε, η and θ) re-
quire phospholipids and 1,2-diacylglycerol for activation, 
whereas activation of the conventional isoforms addi-
tionally depends on Ca 2+  [13] . Atypical isozymes (ζ, ι / λ) 
also require phospholipids but are activated indepen-
dently of 1,2-diacylglycerol and Ca 2+  [13] .
 Isozymes α, β, δ, ε and ζ have been implicated in 
smooth muscle cell contraction via myosin light-chain 
phosphorylation, Ca 2+ channel activation and/or K + 
channel inhibition  [13] , and PKC has been proposed as a 
therapeutic target in pulmonary (arterial) hypertension 
 [12, 14] . Nevertheless, PKC isozymes are differentially ex-
pressed and opposing effects of separate isozymes have 
been described  [12, 15] , highlighting the potential need 
for isozyme-specific targeting.
 Hitherto, little is known about the functional role of 
specific PKC isozymes in the pulmonary vasculature 
 [14] . Cogolludo et al.  [16] reported the involvement of 
PKCζ in TXA2-evoked pulmonary arterial constriction, 
whereas PKCε has been shown to specifically modulate 
hypoxic pulmonary vasoconstriction (HPV)  [17] , which 
has previously been reported to be PKC-dependent  [18] . 
Diminishing effects on HPV following broad-spectrum 
PKC inhibition have been repeatedly described  [18–20] , 
but cPKC isozymes do not seem to play a role in mediat-
ing HPV  [20] . Snow et al.  [21] found that intermittent 
hypoxia augments ET-1-induced pulmonary vasoreac-
tivity in a PKCβ-dependent manner, and it has been 
suggested that PKCδ plays a role in modulating con-
traction in pulmonary arterial smooth muscle cells 
(PASMCs) due to angiotensin II  [22] . Moreover, PKC is 
thought to promote ET-1-induced contraction of hu-
man pulmonary arteries  [23] , possibly via the mediation 
of ET-1-induced inhibition of K v channels, which has 
been shown to be PKC-dependent  [23] . However, the 
functional role of the specific isozyme PKCα in the pul-
monary vasculature remains elusive.
 TXA2, ET-1 and serotonin mediate pulmonary vaso-
constriction via direct G protein-coupled receptor acti-
vation on vascular smooth muscle cells. Hypoxia-in-
duced contraction of isolated PASMCs or pulmonary 
artery rings requires intrinsic mechanisms including
hypoxia sensing and signal transduction  [24] . Alterna-
tively, HPV in the intact lung involves hypoxia sensing 
at the alveolocapillary level, from where the signal is 
conducted retrogradely to the upstream pulmonary ar-
terioles where it is transferred to PASMCs which ulti-
mately contract  [25] . PKC-dependent vasoconstriction 
has been described for each of these vasoconstrictive 
stimuli  [16, 18–21, 26–29] . Nevertheless, the role of PKC 
in TXA2- and serotonin-evoked pulmonary vascular re-
sponsiveness is controversial, since species- and com-
pound-related differences have been observed  [16, 18, 
26, 27] .
 In this study, we dissected the role of PKCα in pulmo-
nary vascular responsiveness to the PAH-associated va-
soconstrictors TXA2, ET-1, serotonin and alveolar hyp-
oxia, by investigating isolated perfused lungs of PKCα-
deficient (PKCα –/– ) mice. In order to compare the 
PKCα-specific effects to the overall PKC or cPKC signal-
ing effects, broad-spectrum PKC inhibition and inhibi-
tion of the conventional PKC isozymes, PKCα and PKCβ, 
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 Materials and Methods 
 Mice 
 All experiments were approved by the local Department of 
Health and Social Affairs (Landesamt für Gesundheit und Soziales, 
LAGeSo, Berlin, Germany). Female PKCα –/– and corresponding 
wild-type (WT) mice (8–11 weeks old) on a 129 SV background 
were used for all experiments. The generation of PKCα –/– mice has 
been described elsewhere  [30] . The WT mice were purchased from 
Charles River Laboratories (Sulzfeld, Germany). All mice were 
housed in individually ventilated cages inside a climate- and light-
cycle-controlled animal house, and were fed a diet of standard 
chow and tap water ad libitum. 
 Isolated Perfused and Ventilated Mouse Lungs 
 Mouse lungs were isolated as described previously  [31, 32] . Brief-
ly, mice were anesthetized i.p. with 160 mg ketamine and 75 mg
xylazin per kilogram of body weight, tracheally intubated, ventilat-
ed and then heparinized by intracardial injection of 125 IU of hep-
arin sodium and exsanguinated. The pulmonary artery and the left 
atrium were cannulated in order to perfuse the lung vasculature with 
sterile and carbonated (20 mmol/l NaHCO 3 ) 37  °  C Krebs-Henseleit 
hydroxyethylamylopectin buffer (1 ml/min; Serag-Wiessner, Naila, 
Germany). Left atrial pressure was set at +2.2 cm H 2 O. Lungs were 
ventilated with negative pressure in a closed chamber (expiratory 
pressure of –4.5 cm H 2 O; inspiratory pressure of –9.0 cm H 2 O; 90 
breaths/min) and hyperinflation (–24 cm H 2 O) was performed at 
4-min intervals. All hardware and software were purchased from 
HSE-Harvard Apparatus (March-Hugstetten, Germany). Mean pul-
monary arterial pressure (Ppa mean) and airway resistance were con-
tinuously monitored. Data were discarded from further analyses if 
lungs had signs of hemostasis, atelectasis or edema.
 Pulmonary Vascular Responsiveness 
 To study the effects of PKC inhibition, broad-spectrum PKC 
inhibitor bisindolylmaleimide I (BIM, 1 μmol/l; Santa Cruz Bio-
technologies, Santa Cruz, Calif., USA), the selective inhibitor of the 
conventional PKC isozymes PKCα and PKCβ Gö6976 (1 μmol/l; 
Merck Millipore, Darmstadt, Germany) or solvent (DMSO <1‰) 
was added to the perfusate. After a steady-state period of approxi-
mately 12 min, increasing doses of ET-1 (10 and 100 nmol/l;
Merck Millipore), serotonin (3, 10 and 30 μmol/l; Sigma-Aldrich, 
Steinheim, Germany) or TP receptor agonist U46619 (30, 100 and 
300 nmol/l; Merck Millipore) were administered into the perfu-
sion buffer for 10 (ET-1)  [9] , 0.5 (serotonin)  [33] or 3 min (U46619) 
 [34] each. To investigate the effects of PKCι inhibition on pulmo-
nary vasoconstriction, the PKCι inhibitor sodium aurothiomalate 
hydrate (ATM, 20 μmol/l; Sigma-Aldrich) was dissolved in the 
perfusion buffer and the vasopressor response was assessed follow-
ing a steady-state period of approximately 28 min  [35, 36] .
 For the analysis of HPV, the murine lungs were isolated as de-
scribed  [37] , and ventilated with negative pressure in a closed 
chamber with a tidal volume of approximately 10 ml/kg body 
weight and an end-expiratory pressure of –2 cm H 2 O. HPV and 
the relationship between pressure (P) and volumetric flow-rate 
(Q) were analyzed as described before  [38, 39] . Briefly, Nω-nitro- 
L -arginine methyl ester hydrochloride (1 mmol/l; Sigma-Aldrich) 
and indomethacin (30 μmol/l; Sigma-Aldrich) were added to the 
perfusate buffer to prevent nitric oxide and prostaglandin synthe-
sis, respectively. After a steady-state period of 10 min, a 4-point 
pressure-flow (P-Q) curve was generated under normoxic condi-
tions by perfusing the lungs with a flow of 0.5, 1, 1.5 or 2 ml/min 
for 30 s each. Perfusion flow was then set at 1 ml/min. After a sec-
ond steady-state period of 4 min, the Ppa mean was recorded for 
12 min in response to a change from normoxic to hypoxic (1% O 2 ) 
ventilation. Approximately 10 minutes after the initiation of HPV, 
a second P-Q curve was generated.
 The difference in Ppa mean (ΔPpa mean) was expressed as a 
percentage and the pressure response to the highest stimulus con-
centration (ET-1, serotonin or U46619), hypoxic ventilation or 
highest perfusion rate (P-Q curve) of the respective control group 
was set at 100%.
 Representative tracings of the Ppa mean in isolated perfused 
and ventilated mouse lungs in response to each vasoconstrictive 
stimulus are shown in online supplementary figure 1 (for all online 
suppl. material, see www.karger.com/doi/10.1159/000443402).
 Microdissection of Intrapulmonary Arteries 
 Mouse lungs were isolated and flushed with NaCl 0.9% for 2 min, 
dissected and instilled with Tissue-Tek ® O.C.T. TM compound 
(Sakura, Staufen, Germany)/PBS (1: 4) through the trachea at a pres-
sure of 20 cm H 2 O for 15 min. Lungs were embedded in Tissue-Tek 
O.C.T. compound and quick-frozen. Serial 8-μm-thick cryosections 
were cut, prepared on membrane slides (membrane slides PEN 1.0, 
Carl Zeiss, Oberkochen, Germany) and fixated with –20  °  C ethanol 
95% for 1.5 min. Hematoxylin and eosin staining was performed, 
followed by dehydration with increasing ethanol concentrations 
(75, 95 and 100%). The air-dried membrane slides were used for la-
ser capture microdissection of intrapulmonary arteries with PALM 
MicroBeam (Carl Zeiss Microimaging GmbH, Bernried, Germany).
 Real-Time Quantitative RT-PCR 
 Gene expression analysis of microdissected intrapulmonary ar-
teries and whole tissue homogenates of dissected and quick-frozen 
PKCα –/– and WT lungs was performed. Total RNA was isolated 
with silica-membrane technology (NucleoSpin ® RNA XS-Kit, 
Macherey & Nagel). Reverse transcription was performed using
a high-capacity reverse-transcription kit (Applied Biosystems, 
Darmstadt, Germany). qRT-PCR was achieved with the 7300 real-
time PCR system. Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) served as a housekeeping control gene (HKG) while TP
receptor and PKC isozymes were genes of interest (GOI).
TaqMan ® gene expression assays were obtained from Applied
Biosystems. The assay IDs were Mm00436917_m1 (TP receptor), 
Mm00435749_m1 (PKCβ), Mm00440861_m1 (PKCγ), 
Mm00440891_m1 (PKCδ), Mm00440894_m1 (PKCε), 
Mm01340228_m1 (PKCθ), Mm00435769_m1 (PKCι), 
Mm00776345_g1 (PKCζ). Primer sequences for PKCη
were CgAgggCTgggTggATCT (forward) and gTCTTCgCA-
TAgCCCTTTgg (reverse). WT mice were considered as controls. 
Relative quantitative gene expression (RQ) was calculated accord-
ing to the comparative Ct method: ΔCt: Ct GOI – Ct HKG ; ΔΔCt: 
ΔCt PKCα–/–  or WT – ΔCt mean WT ; RQ: 2 –ΔΔCT .
 Statistical Analysis 
 Two-way ANOVA was performed for the comparison of dose-
response curves and the Mann-Whitney U test for the comparison 
of data between 2 groups. p  ≤ 0.05 was considered to be statisti-
cally significant and p values are presented as follows:  *  p  ≤ 0.05, 
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 U46619 Caused Pulmonary Vascular 
Hyperresponsiveness in PKCα-Deficient Mice 
 To elucidate the role of PKCα in pulmonary vascular 
responsiveness, the effects of PKC inhibition and PKCα 
deficiency were analyzed in isolated perfused and venti-
lated mouse lungs. Under basal conditions, the Ppa mean 
was unaffected by pharmacological broad-spectrum PKC 
inhibition with BIM (mean ± SEM: 10.11 ± 0.09 cm H 2 O) 
compared to solvent treatment (10.23 ± 0.12 cm H 2 O), by 
selective inhibition of the conventional PKC isozymes 
PKCα and PKCβ with Gö6976 (10.51 ± 0.16 cm H 2 O) 
compared to solvent treatment (10.30 ± 0.15 cm H 2 O) or 
by PKCα deficiency (9.30 ± 0.18 cm H 2 O) compared to 
the WT control (9.81 ± 0.15 cm H 2 O).
 Pulmonary vascular responsiveness to the TP receptor 
agonist U46619 was reduced by trend following broad-
spectrum PKC inhibition when compared to solvent treat-
ment ( fig.  1 a), suggesting a moderate role of PKC in 
thromboxane-evoked pulmonary vasoconstriction as 
shown before  [26] . Selective cPKC inhibition had no effect 
on the U46619-evoked pressure response ( fig. 1 b), which 
is in line with previous findings  [16] . Surprisingly, U46619-
induced pulmonary vascular responsiveness was highly 
increased in PKCα –/– lungs compared to the correspond-
ing WT lungs ( fig. 1 c). This pulmonary vascular hyperre-
sponsiveness in PKCα –/– mice was, at first sight, contra-
dictory, as PKCα is thought to promote vasoconstriction 
 [40, 41] . To analyze whether this hyperresponsiveness is 
(1) thromboxane-specific or (2) specific for vasoconstric-
tion initiated at the vascular site via direct G protein-cou-
pled receptor activation, we studied pulmonary vascular 
responsiveness to ET-1 and serotonin as well as HPV.
 ET-1-Induced Pulmonary Vascular Responsiveness Is 
PKCα-Dependent 
 Both broad-spectrum PKC inhibition ( fig. 2 a) and the 
selective inhibition of the cPKC isozymes PKCα and 
PKCβ ( fig. 2 b) reduced the pulmonary vasoconstriction 
induced by ET-1 application. Furthermore, pulmonary 
vascular responsiveness to ET-1 was markedly reduced 
by about 40% in PKCα –/– mice compared to in WT mice 
( fig. 2 c), suggesting that PKCα is the main PKC isozyme 
promoting the pulmonary vasopressor response to ET-1.
 In contrast, serotonin-induced pulmonary vascular 
responsiveness was not altered by broad-spectrum PKC 
inhibition ( fig. 3 a) or PKCα deficiency ( fig. 3 b). 
 HPV Is PKC-Dependent but Not PKCα-Dependent 
 Hypoxic ventilation led to the characteristic increase 
in Ppa mean. As shown before by Weissmann et al.  [18] , 
PKC inhibition distinctly reduced HPV ( fig. 4 a). Consis-





































































 Fig. 1. PKCα deficiency induces pulmonary vascular hyperrespon-
siveness to TP receptor agonist U46619.  a In isolated perfused and 
ventilated mouse lungs, U46619-evoked pulmonary vasoconstric-
tion was reduced by trend following treatment with the PKC in-
hibitor BIM (1 μmol/l) compared to solvent treatment.  b Selective 
inhibition of conventional PKC isozymes by Gö6976 (1 μmol/l) 
had no effect on pulmonary vascular responsiveness to U46619.
 c PKCα –/– mice showed a significantly greater increase in Ppa com-
pared to the corresponding WT mice upon U46619 stimulation. 
Data represent the percentage of the pressure response observed 
in the respective control group at highest concentration. Values 
are shown as mean + SEM.  a n = 11 per group;  b ,  c n = 6–7 per 
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minished Ppa mean over the course of all 4 flow rates 
under hypoxia, whereas the flow-induced increase in Ppa 
mean was unaltered by PKC inhibition under normoxic 
conditions ( fig. 4 b). PKCα deficiency, however, did not 
affect HPV ( fig. 4 c) or P-Q curves ( fig. 4 d) when com-
pared to WT mice.
 Thus, the initially observed pulmonary hyperrespon-
siveness to U46619 in PKCα –/– mice was most likely 
thromboxane-specific. To elucidate the underlying mech-
anism of the U46619-evoked hyperresponsiveness, we 
performed quantitative mRNA analyses of the TP recep-
tor and PKC isozymes.
 mRNA Expression of TP Receptor and Atypical PKCι 
Is Upregulated in Microdissected Intrapulmonary 
Arteries from PKCα –/– Mice 
 mRNA expression levels of the TP receptor and PKC 
isozymes were measured in laser-capture microdissected 
intrapulmonary arteries and whole-lung tissue homoge-
nates from naïve PKCα –/– and WT mice. The rank order 
of PKC isozyme expression in the WT intrapulmonary 
arteries was as follows: PKCδ > PKCε > PKCζ > PKCι > 
PKCα > PKCη > PKCβ > PKCθ > PKCγ (online suppl. 
fig. 2). Notably, TP receptor mRNA expression in micro-






































































 Fig. 2. PKCα is required for ET-1-induced pulmonary vasocon-
striction. Broad-spectrum PKC inhibition (BIM; 1 μmol/l;  a ),
selective inhibition of conventional PKC isozymes (Gö6976;
1 μmol/l;  b ) or PKCα deficiency ( c ) decreased the Ppa response 
towards ET-1 compared to the respective control group in isolated 
perfused mouse lungs. Data represent the percentage of the pres-
sure response seen in the respective control group at highest con-
centration. Values are shown as mean + SEM. n = 4–7 per group. 















































 Fig. 3. Serotonin-evoked pulmonary vaso-
constriction does not involve PKCα.  a Fol-
lowing PKC inhibitor application (BIM;
1 μmol/l), pulmonary vascular responsive-
ness to serotonin was comparable to the va-
sopressor response observed in the solvent-
treated control group.  b Similarly, PKCα 
deficiency had no effect on serotonin-in-
duced pulmonary vasoconstriction. Data 
represent the percentage of the pressure re-
sponse observed in the respective control 
group at highest concentration. Values are 
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was 2.7-fold greater compared to WT mice ( fig. 5 a). Sim-
ilarly, PKCι mRNA levels were highly elevated in the
intrapulmonary arteries from PKCα –/– mice (2.7-fold; 
 fig. 5 b).
 In contrast, mRNA expression levels of conventional 
isozymes PKCβ and PKCγ, novel isozymes PKCδ, PKCε, 
PKCη, PKCθ and the atypical isozyme PKCζ were similar 
in the intrapulmonary arteries of PKCα –/– and WT mice 
(online suppl. table 1).
 The elevated expression of TP receptor and PKCι in 
PKCα-deficient lungs seems to be specific to the pulmonary 
arteries, since no differential expression of TP receptor and 
PKC isozyme in whole-lung tissue homogenates was de-































































































 Fig. 4. HPV requires PKC, but not spe-
cifically PKCα. PKC inhibition (BIM;
1 μmol/l) reduced HPV (1% O 2 ) ( a ) and the 
flow (Q)-induced increase in Ppa under 
hypoxia ( b ) but not under normoxia. PKCα 
deficiency did not alter HPV ( c ) or pres-
sure-flow curves ( d ). Data represent the 
percentage of the pressure response to hy-
poxic ventilation or the highest flow rate 
(Q) seen in the respective control group. 
Values are shown as mean + SEM. a, b n = 
5 per group; c, d n = 8–9 per group.  * *  p  ≤ 





































 Fig. 5. PKCα deficiency leads to increased 
TP receptor and PKCι mRNA expression 
in intrapulmonary arteries.  a ,  b mRNA ex-
pression analysis from microdissected in-
trapulmonary arteries showed a 2.7-fold 
increase in the expression of TP receptor 
and PKCι mRNA in PKCα –/– compared to 
in WT pulmonary arteries. Data represent 
the relative quantitative gene expression: 
mRNA expression levels were normalized 
to GAPDH levels and compared to expres-
sion levels in WT mice using the com-
parative Ct method. Values are shown as 
mean + SEM. n = 5–7 per group.  *  p  ≤ 0.05; 
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 Elevated PKCι Expression in PKCα –/– Pulmonary 
Arteries Does Not Contribute to Vascular 
Hyperresponsiveness to U46619 in PKCα –/– Lungs 
 As revealed by mRNA analysis, increased TP receptor 
expression possibly leads to pulmonary vascular hyper-
responsiveness to U46619 in PKCα –/– mice. However, 
since PKCι has been shown to mediate contraction of the 
rat corpus cavernosum  [42] , a contribution by PKCι to 
the vascular hyperresponsiveness that we observed also 
seems possible. To elucidate the functional role of upreg-
ulated PKCι in the vasculature of PKCα –/– lungs, the ef-
fect of PKCι inhibitor ATM on U46619-evoked pulmo-
nary vasoconstriction was assessed. Basal Ppa mean was 
unaffected by PKCι inhibition (mean ± SEM: 9.64 ± 0.23 
cm H 2 O) compared to the solvent treatment (9.36 ± 0.33 
cm H 2 O). Importantly, PKCι inhibition did not reduce 
pulmonary vascular hyperresponsiveness to U46619 in 
PKCα –/– mice ( fig. 6 ), allowing us to conclude that besides 
elevated TP receptor expression in intrapulmonary arter-
ies, increased PKCι expression is most likely not causative 
for this increased vasopressor response.
 Discussion 
 This study demonstrates PKC isozyme-specific func-
tions in the pulmonary vasculature. PKCα contributed to 
pulmonary vasoconstriction induced by ET-1. Converse-
ly, however, PKCα deficiency led to pulmonary vascular 
hyperresponsiveness to TXA2, possibly via the upregula-
tion of the TP receptor in the intrapulmonary arteries. 
Furthermore, HPV, although diminished following PKC 
inhibition, did not depend on the isozyme, PKCα, where-
as serotonin-induced pulmonary vasoconstriction was 
unaffected by both PKC inhibition or PKCα deficiency.
 ET-1-evoked pulmonary vasoconstriction was reduced 
by approximately 40% in PKCα-deficient mice compared 
to WT mice, suggesting a prominent role for the PKC iso-
zyme, PKCα, in the pulmonary vasopressor response to 
ET-1. These findings are consistent with a study by Feng 
et al.  [41] demonstrating a significant role for PKCα sig-
naling in ET-1-induced coronary microvascular vasocon-
striction. Moreover, ET-1-induced contraction of isolated 
mesenteric arteries was reduced following treatment with 
a PKCα inhibitor peptide  [43] . Interestingly, in a study by 
Weigand et al.  [44] , ET-1-induced contraction in pulmo-
nary arteries from chronically hypoxic rats was shown to 
be unaffected by PKC inhibition, possibly pointing to al-
tered mechanisms of ET-1-induced contraction under hy-
poxic conditions, which require further investigations. In 
contrast to the vasopressor response to ET-1, isozyme 
PKCα did not contribute to HPV, which has previously 
been shown to depend on PKC  [18–20] and particularly 
isozyme PKCε  [17] , again indicating isozyme-specific 
functions in the pulmonary vasculature.
 Surprisingly, PKCα deficiency led to pulmonary vas-
cular hyperresponsiveness to the TXA2 analog U46619. 
As PKCα is proposed to be a promoter of smooth muscle 
cell contraction  [40, 41, 43] , this finding was unexpected. 
TXA2 is a prostanoid derived from arachidonic acid, 
which exerts its constrictive effects by binding TP recep-
tors on vascular smooth muscle cells, leading to the inhi-
bition of voltage-gated K + channels, membrane depolar-
ization, the activation of L-type Ca 2+ channels, and ulti-
mately smooth muscle cell contraction  [16] . The throm-
boxane system has been implicated in the pathogenesis of 
PAH  [2, 45] . In this study, we observed that the pulmo-
nary vascular hyperresponsiveness to U46619 in isolated 
PKCα –/– lungs coincided with pulmonary arterial TP re-
ceptor upregulation. Although it is tempting to speculate 
that compensatory TP receptor upregulation is a result of 
constitutive PKCα deficiency in PKCα –/– mice, the exact 
underlying mechanisms leading to this upregulation in 
PKCα deficiency remain elusive. Also, the pathophysio-
logical impact of this observation is unclear. However, 
since neither broad-spectrum PKC inhibition nor selec-


























 Fig. 6. PKCι inhibition does not reduce vascular hyperresponsive-
ness to U46619 in PKCα –/– lungs. Following application of PKCι 
inhibitor ATM (20 μmol/l), pulmonary vasoconstriction induced 
by TP receptor agonist U46619 was unaltered (p = 0.17) compared 
to solvent treatment. Data represent the percentage of the pressure 
response seen in the respective control group at highest concentra-
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pressor response to U46619, the hyperresponsiveness in 
PKCα –/– lungs that we observed seems to rather be a re-
sult of TP receptor upregulation in the intrapulmonary 
arteries than a direct effect of the absence of PKCα.
 To our knowledge, there are no published data on 
PKCα expression in PAH patients. A study by Shi et al. 
 [46]  demonstrated decreased PKCα expression in the 
pulmonary arteries of rats with hypoxia-induced pulmo-
nary hypertension. Moreover, increased TP receptor den-
sity has been observed in the right ventricular tissue of 
PAH patients  [47] .
 Besides TP receptor expression, PKCι expression was 
shown to be elevated in the intrapulmonary arteries of 
PKCα –/– mice. However, the role of PKCι in pulmonary 
vasoconstriction is currently unknown. A large body of 
literature has discussed PKCι as a tumor oncogene  [48] , 
but very little is known about its role in adult pulmonary 
vasculature. PKCι activation during embryonic vasculo-
genesis  [49] and a potential role for PKCα and PKCι in 
phenylephrine-induced contraction of the rat corpus ca-
vernosum have been proposed  [42] . However, compen-
sative modulation of pulmonary vascular function by 
PKCι in PKCα –/– mice is unlikely, since pulmonary vas-
cular hyperresponsiveness to U46619 was not reduced in 
PKCα –/– lungs following PKCι inhibition, as shown in 
this study. In line with this notion, it has been reported 
that treatment with the PKCι inhibitor sodium aurothio-
malate failed to inhibit adrenaline-induced constriction 
of rat anterior mesenteric artery and vein  [50] as well as 
epidermal growth factor-urogastrone-evoked contrac-
tion in isolated longitudinal smooth muscle strips from 
guinea-pig stomach  [51] . Nevertheless, to our knowledge, 
this is the first report on the effects of selective PKCι in-
hibition on pulmonary vasoconstriction focusing on the 
specific response to U46619 in PKCα –/– lungs, so a poten-
tial PKCι-mediated modulation of pulmonary vascular 
function needs to be further evaluated in future studies.
 Remarkably, serotonin-induced pulmonary vasocon-
striction was not altered by the PKC inhibitor BIM
(1 μmol/l) or PKCα deficiency in isolated perfused naïve 
mouse lungs. This is consistent to some extent with the 
report by Kaye et al.  [27] , showing that the feline pulmo-
nary vasoconstrictor response to serotonin was unaffect-
ed by pretreatment with the PKC inhibitor staurosporine 
or calphostin C. Nevertheless, in the same study, stauro-
sporine was observed to diminish the pulmonary arterial 
pressor response to serotonin in isolated perfused rat 
lungs  [27] . BIM (10 μmol/l) also reduced the hyperre-
sponsive vasoconstriction towards serotonin in isolated 
perfused lungs of ovalbumin-sensitized and ovalbumin-
challenged mice  [9] . In addition, the PKC inhibitors 
Gö6976 and staurosporine have been shown to reduce 
serotonin-evoked reactivity of rat PASMCs  [28] or the 
pulmonary vasculature in isolated canine lungs  [29] , re-
spectively. However, staurosporine is the precursor of 
BIM and, with a relatively high affinity to other protein 
kinases, it is less PKC-specific than BIM  [52] . Gö6976 is 
a selective inhibitor of conventional PKCα and PKCβ.
 Our data suggest that serotonin-evoked pulmonary va-
soconstriction is not mediated via PKC, and particularly 
not via PKCα in isolated naïve mouse lungs. Several expla-
nations for the seemingly contradictory findings are pos-
sible, including species specificity, differences in the com-
plexity of models or the varying isozyme selectivity profiles 
of different PKC inhibitors, particularly when applied at 
different concentrations. Since the BIM-evoked half maxi-
mal inhibition (IC 50 ) for relevant conventional and novel 
PKC isozymes ranges roughly from 8 to 210 nmol/l (ac-
cording to the manufacturer), the currently employed con-
centration of 1 μmol/l BIM indicates an adequate cPKC/
nPKC inhibition under physiological conditions, and is
the preferred working concentration for vasoconstriction 
analysis in naïve isolated perfused lungs  [53, 54] . On the 
other hand, IC 50 for atypical PKCζ requires 5.8 μmol/l of 
BIM. Thus, the somewhat weak reduction of U46619-in-
duced vasoconstriction that we observed can possibly be 
explained by only a partial inhibition of PKCζ, as PKCζ has 
been shown to promote U46619-evoked pulmonary vaso-
constriction  [16] . Moreover, as we could not entirely rule 
out PKCι-mediated pulmonary vasoconstriction, the weak 
or failed reduction of the vasopressor responses to U46619 
and serotonin, respectively, by BIM, may also be in part 
explained by the fact that PKCι was probably not affected 
or was incompletely affected by 1 μmol/l of BIM.
 In summary, we identified the PKC family as important 
agonist-specific modulators of pulmonary vascular func-
tion. HPV was affected by broad-spectrum PKC inhibi-
tion, but not by a deficiency of the PKCα isozyme. In con-
trast, the ET-1-evoked pulmonary vasoconstriction, which 
is assumed to be an important feature of PAH pathophys-
iology, was promoted by PKCα. However, PKCα deficien-
cy led to pulmonary vascular hyperresponsiveness towards 
TXA2, which coincided with increased TP receptor ex-
pression. This finding may be of clinical relevance and 
should be kept in mind when discussing PKC isozymes 
and, in particular, PKCα, as potential targets for PAH ther-
apy. Further studies are warranted to analyze whether the 
pharmacological, long-term inhibition of PKCα counter-
acts its possible beneficial effects on the pulmonary vascu-
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